• Japanese
  • Korean
  • Chinese
Cover Image

Oral Transmucosal Drug Delivery: Products, Players, Markets & Forecasts

Greystone Research Associates is pleased to announce the publication of a new market study. Oral Transmucosal Drug Delivery: Products, Players, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for drug delivery films, sprays, lozenges, wafers and orally dissolvable tablets that are designed to be administered into the oral cavity and be absorbed systematically via the oral mucosa. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Safety, Compliance and Oral Drug Technology

In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism. On the provider side, the development of alternative methods of drug administration has improved the ability of physicians to manage specific problems. Practitioners now recognize the rapid onset, relative reliability, and the general lack of patient discomfort when drugs are administered by the transmucosal route. We expect this market to experience healthy growth through 2016 as absorbable solid dosage technology is applied to existing drugs and as absorbable formulations become an important route of administration for an increasing number of new NCEs. Growth in this sector will also be driven by the pressure to extend market protection for numerous existing drugs with soon-to-expire patents.


  • Analyzes and evaluates oral transmucosal drug delivery technology platforms and their impact on the market
  • Analyzes oral transmucosal drug products and pipeline product candidates
  • Provides assessments of key oral transmucosal drug therapeutic categories
  • Provides market data and forecasts to 2016
  • Profiles market participants, their product development activities and strategies


Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

Table of Contents

Executive Summary

Drug Delivery Market Dynamics

  • Evolution in Drug Development
  • Market and Demand Drivers
    • Shifting Patient Demographics
    • The Impact of Generics
    • Managed Care Initiatives
  • Competitive Landscape

Competing Transmucosal Delivery Technologies

  • Oral Sprays
  • Buccal Films and Tablets
  • Sublingual Films and Wafers

Commercial Transmucosal Formulation Platforms

  • Adversa
  • BEMA
  • Bioadhesive Delivery System
  • Corplex
  • FluidCrystal
  • Intravail
  • Lauriad
  • OraDisc
  • OraVescent
  • RapidMist
  • Transmucosal Film

Oral Transmucosal Drug Technology Factors

  • Absorption
  • Bioavailability
  • Adhesion
  • Pharmacokinetics

FDA-Approved Oral Transmucosal Products

  • Asenapine
  • Buprenorphine (3 products)
  • Ergotamine
  • Fentanyl (8 products)
  • Hydergine
  • Isosorbide dinitrate (2 products)
  • Miconazole
  • Nitroglycerin (3 Products)
  • Ondansetron
  • Testosterone
  • Zolpidem (3 products)
  • Zuplenz

Important Pipeline Product Candidates

  • Agomelatine
  • ALKS 5461
  • Buprenorphine
  • Buprehorphine
  • Buprenorphine
  • Cannabinoid
  • Desmopressin
  • Fentanyl
  • Fentanyl
  • Granisetron
  • Insulin
  • Ramelteon
  • Sufentanil
  • Sumatriptan
  • Zolpidem
  • Zolpidem

Market Assessments & Forecasts

  • Addiction
  • Anti-infectives
  • Cardiology
  • Diabetes
  • Immunology
  • Infectious Disease
  • Neurology
  • Oncology
  • Pain Management
  • Sexual Health
  • Vaccines

Market Factors

  • Formulations and Proprietary Platforms
  • Government Regulations
  • Patent Expiration and Rx-to-OTC Switching

Company Profiles

Show More
Get Notified
Email me when related reports are published